Abstract:Amyloid beta (Aβ) is the main component of the amyloid plaques that accumulate in the brains of Alzheimer patients. The present study was conducted to investigate whether the combined treatment with selenium (Se) and zinc (Zn) offers more beneficial effects than that provided by either of them alone in reversing Aβ 25–35 -induced neurotoxicity in PC12 cells. Cells were pretreated with 0.1 μmol/L of Se and Zn for 4 h, after treated with 10 mmol/L Aβ 25–35 for 24 h. Cells were divided into control and five treated groups, and received either 10 mmol/L Aβ 25–35, 10 mmol/L Aβ 25–35 + 0.1 μmol/L Se, 10 mmol/L Aβ 25–35 + 0.1 μmol/L Zn, 10 mmol/LAβ 25–35 + 0.1 μmol/L Se + 0.1 μmol/L Zn, or 0.1 μmol/L Se + 0.1 μmol/L Zn. The result showed that cell viability was decreased in MTT metabolic rate; LDH release and MDA, H 2 O 2 , and NO levels were increased and the GSK-3β and phosphorylated tau protein level were increased in Aβ 25–35 -treated group ( P < 0.05 or P < 0.01), which whole changes were attenuated by Se and Zn and Se combined Zn. In order to evaluate whether the Se and Zn have an effect on processing pathway of amyloid precursor protein (APP), we examined the activity of γ-secretase in primary cultured cortical neuron cells. ELISA analysis showed that Se and Zn could inhibit the activity of γ-secretase. Then we also investigated the effect of Se and Zn on the Aβ 1–40 concentration and APP-N-terminal fragment expression from APP695 stably transfected Chinese hamster ovary (CHO) cells. APP695 stably transfected CHO cells were treated with 0.1 μmol/L Se and Zn; cells were divided into control and four treated groups, which received either 0.5 M DAPT, 0.1 μmol/L Se, 0.1 μmol/L Zn, or 0.1 μmol/L Se + 0.1 μmol/L Zn. Se and Zn could decrease Aβ 1–40 production and increase the APP-N-terminal fragment protein expression. These experiments indicate that Se and Zn have a protective effect on AD pathology that a possible mechanism is inhibiting the activity of γ-secretase to decreasing Aβ 1–40 production further influencing the APP processing. Altogether, our findings may provide a novel therapeutic target to treat AD sufferers.

Se/Ru nanoparticles as inhibitors of metal-induced Aβ aggregation in Alzheimer's disease

Enantiomers of Cysteine-Modified SeNPs (d/lsenps) As Inhibitors of Metal-Induced Aβ Aggregation in Alzheimer's Disease.

Dual-functional selenium nanoparticles bind to and inhibit amyloid β fiber formation in Alzheimer's disease

Chiral Penicillamine-Modified Selenium Nanoparticles Enantioselectively Inhibit Metal-Induced Amyloid Β Aggregation for Treating Alzheimer’s Disease

A Ru3+-Functionalized-NMOF Nanozyme as an Inhibitor and Disaggregater for β-Amyloid Aggregates

A Ru3+-functionalized-NMOF Nanozyme As an Inhibitor and Disaggregator of Β-Amyloid Aggregates

Copolymer Polydopamine Nanoparticles as Multifunctional Nanoinhibitors for Modulating β-Amyloid Aggregation

Inhibition of metal-induced amyloid aggregation using light-responsive magnetic nanoparticle prochelator conjugates

Biogenic Selenium Nanoparticles Attenuate Aβ 25–35 -Induced Toxicity in PC12 Cells via Akt/CREB/BDNF Signaling Pathway

Biogenic Selenium Nanoparticles Attenuate Aβ25–35-Induced Toxicity in PC12 Cells via Akt/CREB/BDNF Signaling Pathway

Serum albumin-embedding copper nanoclusters inhibit Alzheimer's β-amyloid fibrillogenesis and neuroinflammation

Selenium and Zinc against Aβ 25–35 -Induced Cytotoxicity and Tau Phosphorylation in PC12 Cells and Inhibits γ-cleavage of APP

C3N Nanodots Inhibits Aβ Peptides Aggregation Pathogenic Path in Alzheimer's Disease.

Multiple Effects of Polydopamine Nanoparticles on Cu 2+ -Mediated Alzheimer's Β-Amyloid Aggregation

Quercetin-loaded Selenium Nanoparticles Inhibit Amyloid-Β Aggregation and Exhibit Antioxidant Activity

Finding the best location: Improving the anti-amyloid ability of ruthenium(III) complexes with pyridine ligands

Sulfur Nanoparticles with Novel Morphologies Coupled with Brain-Targeting Peptides RVG As a New Type of Inhibitor Against Metal-Induced Aβ Aggregation

Α‐synuclein As a Target for Metallo‐Anti‐Neurodegenerative Agents

Ruthenium Dioxide Nanoparticles Treat Alzheimer's Disease by Inhibiting Oxidative Stress and Alleviating Neuroinflammation

A Novel Synthesis of Selenium Nanoparticles Encapsulated PLGA Nanospheres with Curcumin Molecules for the Inhibition of Amyloid Β Aggregation in Alzheimer's Disease

Inhibition of metal-induced amyloid beta-peptide aggregation by a blood-brain barrier permeable silica-cyclen nanochelator